Abstract 1125P
Background
With effective systemic therapies for melanoma, patients (pts) with clinical stage III (cS3) disease, previously first treated with operation, are now increasingly offered neoadjuvant therapy (NST). Excellent pathologic response rates (pRR) and improved event-free survival with NST have now raised questions about the extent of operation required for those with a favorable pRR, particularly pts with limited disease at baseline. PET-CT, for baseline and post-NST staging, is used primarily to exclude distant disease. While data exist showing nodal metabolic response is unreliable for predicting a pathologic complete response (pCR), data specifically evaluating nodal imaging to nodal pathology correlation are scarce. We evaluated correlation between PET-CT nodal findings and operative pathology.
Methods
With IRB approval, we identified cS3 melanoma pts treated with NST 2011-2024 and operated on at our institution. We included pts with both pre- and post-NST PET-CT imaging. Imaging response was reported per RECIST v1.1 and EORTC PET response criteria. Pathology assessment was per IMNC guidelines.
Results
Of 60 pts, median age was 61 years, 50% were female. NST was immunotherapy (IO) + targeted therapy (IO+TT) in 48% and IO in 42%. Median NST duration was 12 weeks. Imaging response rate (iRR) overall was 60% per RECIST and 57% per EORTC PET and was higher for IO+TT (72%) than IO (48%). Pathology evaluation of a median 15 nodes (LNs)/pt showed pCR or near-pCR (≤10% viable tumor) in 28/60 (47%) with 65% having a pRR with <50% viable tumor. Among pts with residual disease, the median number of positive LNs at operation was 2 (IQR 1-4). At baseline, 42% of pts had 1 positive LN, with a 56% iRR and 48% pRR with a 44% pCR/near-pCR rate, while 58% of pts had ≥2 positive LN with a 63% iRR and 66% pRR with 46% having a pCR/near-pCR. Enumerating the number of LN+ on PET-CT underestimated extent of disease: 27% had a greater number of involved LNs on pathology assessment than on preoperative imaging (32% for pts with 1 LN+, 23% for pts with ≥2 LN+ nodes on baseline imaging).
Conclusions
PET-CT nodal imaging should be interpreted cautiously as it may underestimate the number of affected LNs. Over-reliance on imaging to guide surgical management following NST may lead to suboptimal treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Stoff: Financial Interests, Personal, Invited Speaker: Merck Serono, MSD, Medison Pharma, Novartis. M.S. Block: Financial Interests, Institutional, Research Funding: BMS, Alkermes, Genentech, Merck, nFerence, Pharmacyclics, Regeneron, Transgene; Financial Interests, Personal and Institutional, Research Funding, Non-paid advisory bord member: Marker Therapeutics, Sorrento, TILT biotherapeutics, Viewpoint molecular therapeutics. T.J. Hieken: Financial Interests, Institutional, Research Funding: Genentech, SkylineDX. All other authors have declared no conflicts of interest.
Resources from the same session
1101P - Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Presenter: Mario Mandalà
Session: Poster session 04
1102P - Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
Presenter: Allison Betof Warner
Session: Poster session 04
1103P - Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma
Presenter: Lilit Karapetyan
Session: Poster session 04
1104P - Early time-point <sup>18</sup>F-FDG-PET/CT at week four (W4) as a prognostic biomarker of survival in metastatic melanoma (mM) patients (pts) on immunotherapy
Presenter: Nezka Hribernik
Session: Poster session 04
1105P - Predicting the outcomes of advanced cutaneous melanoma cases following discontinuation of immune checkpoint inhibition
Presenter: Ka-won Noh
Session: Poster session 04
1106P - NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
Presenter: Mora Guardamagna
Session: Poster session 04
1107P - Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab
Presenter: Jessica Hassel
Session: Poster session 04
1108P - Impact of quantitative imaging of all disease on the prognostic value of <sup>18</sup>F-FDG PET/CT in patients treated with immunotherapy for metastatic melanoma
Presenter: Robert Jeraj
Session: Poster session 04
1109P - Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors
Presenter: Eva Ellebaek
Session: Poster session 04
1110P - Follow-up brain imaging in patients with melanoma brain metastasis and immune checkpoint inhibitors
Presenter: Imren Ozdamar
Session: Poster session 04